Cargando…

269 Refractory Chronic Urticaria Treated with Omalizumab

BACKGROUND: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with angioedema(1). It affects 0.1% of the population, it is estimated that approximately 15 to 25% of the population will have hives at some point in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Saenz, Martinez, Del Pozo, Ramírez, JJ, Lopez Tiro, Vera, Javier Gomez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: World Allergy Organization Journal 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513034/
http://dx.doi.org/10.1097/01.WOX.0000412026.08889.ad
_version_ 1782251860151762944
author Saenz, Martinez
Del Pozo, Ramírez
JJ, Lopez Tiro
Vera, Javier Gomez
author_facet Saenz, Martinez
Del Pozo, Ramírez
JJ, Lopez Tiro
Vera, Javier Gomez
author_sort Saenz, Martinez
collection PubMed
description BACKGROUND: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with angioedema(1). It affects 0.1% of the population, it is estimated that approximately 15 to 25% of the population will have hives at some point in their lives.(2) About 80% of UC patients are diagnosed as idiopathic chronic urticaria and that no cause is identified, 3 experiencing deterioration in their quality of life affecting your work, social relationships, schemes requiring multiple medications and doses higher than usual. This study proposes Omalizumab (anti-IgE humanized antibody) as a treatment for Refractory Chronic Urticaria (RCU) OBJECT: Demonstrate Omalizumab's effectiveness in the treatment of Refractory Chronic Urticaria. METHODS: A clinical study, was carried out to evaluate the effectiveness of the Omalizumab's treatment on RCU diagnosed patient, including male and female patients ages 12 to 50 diagnosed with RCU, with Scorad higher tan 30 points. We made a questionnaire to know about the patient's family background, skin symptoms beginning, administration of drugs such sistemic steroids, inmunosupresors, calceurine inhibitors, presence of inmunotherapy and age of start. Omalizumab was administered on doses according patient's weight and IgE levels, bimonthly or monthly according to treatment guides. Severeness level was calculated with scorad every 1 month, with IgE seric level measurement and life quality questionnaire. RESULTS: 5 patients diagnosed with RCU were included in the group of Omalizumab and 5 patients in the control group (placebo). All patients were female. A gradual decrease on the life quality score and in Score, with a significant P under 0.05 was observed on all patients treated with omalizumab compared with patient in the group with placebo. CONCLUSIONS: Treatment with Omalizumab progressively decreases the severeness level on RCU, with a significant improvement on the patient's life quality.
format Online
Article
Text
id pubmed-3513034
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher World Allergy Organization Journal
record_format MEDLINE/PubMed
spelling pubmed-35130342012-12-21 269 Refractory Chronic Urticaria Treated with Omalizumab Saenz, Martinez Del Pozo, Ramírez JJ, Lopez Tiro Vera, Javier Gomez World Allergy Organ J Abstracts of the XXII World Allergy Congress BACKGROUND: Chronic urticaria (CU) is a common disorder characterized by recurrent episodes of urticaria pruritic erythematous lesions, associated with angioedema(1). It affects 0.1% of the population, it is estimated that approximately 15 to 25% of the population will have hives at some point in their lives.(2) About 80% of UC patients are diagnosed as idiopathic chronic urticaria and that no cause is identified, 3 experiencing deterioration in their quality of life affecting your work, social relationships, schemes requiring multiple medications and doses higher than usual. This study proposes Omalizumab (anti-IgE humanized antibody) as a treatment for Refractory Chronic Urticaria (RCU) OBJECT: Demonstrate Omalizumab's effectiveness in the treatment of Refractory Chronic Urticaria. METHODS: A clinical study, was carried out to evaluate the effectiveness of the Omalizumab's treatment on RCU diagnosed patient, including male and female patients ages 12 to 50 diagnosed with RCU, with Scorad higher tan 30 points. We made a questionnaire to know about the patient's family background, skin symptoms beginning, administration of drugs such sistemic steroids, inmunosupresors, calceurine inhibitors, presence of inmunotherapy and age of start. Omalizumab was administered on doses according patient's weight and IgE levels, bimonthly or monthly according to treatment guides. Severeness level was calculated with scorad every 1 month, with IgE seric level measurement and life quality questionnaire. RESULTS: 5 patients diagnosed with RCU were included in the group of Omalizumab and 5 patients in the control group (placebo). All patients were female. A gradual decrease on the life quality score and in Score, with a significant P under 0.05 was observed on all patients treated with omalizumab compared with patient in the group with placebo. CONCLUSIONS: Treatment with Omalizumab progressively decreases the severeness level on RCU, with a significant improvement on the patient's life quality. World Allergy Organization Journal 2012-02-17 /pmc/articles/PMC3513034/ http://dx.doi.org/10.1097/01.WOX.0000412026.08889.ad Text en Copyright © 2012 by World Allergy Organization
spellingShingle Abstracts of the XXII World Allergy Congress
Saenz, Martinez
Del Pozo, Ramírez
JJ, Lopez Tiro
Vera, Javier Gomez
269 Refractory Chronic Urticaria Treated with Omalizumab
title 269 Refractory Chronic Urticaria Treated with Omalizumab
title_full 269 Refractory Chronic Urticaria Treated with Omalizumab
title_fullStr 269 Refractory Chronic Urticaria Treated with Omalizumab
title_full_unstemmed 269 Refractory Chronic Urticaria Treated with Omalizumab
title_short 269 Refractory Chronic Urticaria Treated with Omalizumab
title_sort 269 refractory chronic urticaria treated with omalizumab
topic Abstracts of the XXII World Allergy Congress
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513034/
http://dx.doi.org/10.1097/01.WOX.0000412026.08889.ad
work_keys_str_mv AT saenzmartinez 269refractorychronicurticariatreatedwithomalizumab
AT delpozoramirez 269refractorychronicurticariatreatedwithomalizumab
AT jjlopeztiro 269refractorychronicurticariatreatedwithomalizumab
AT verajaviergomez 269refractorychronicurticariatreatedwithomalizumab